Campaign

Company Summary :

The company’s lead drug, NTP42, is viewed by many key opinion leaders as having the potential to dramatically change the treatment of Pulmonary Arterial Hypertension, or “PAH”, a devastating heart and lung disease. Amongst these experts includes Dr Sandeep Sahay, a world leading PAH clinical consultant based in Heuston, Texas. Today, ATXA is a pre-revenue pharma company currently in clinical development, where the progress it has made on NTP42 through numerous, successful clinical milestones has brought it to the “Phase II Ready” stage ahead of clinical trials in PAH patients. Demonstration of NTP42’s clinical efficacy (that it works in treating patients) in these Phase II trials running from late 2025 would boost ATXA’s equity valuation enormously (10 – 20 fold) and position it for lucrative M&A or licencing deals with global pharmaceutical players. Back in late 2023, we raised just over €2m on the Spark platform, in association with other existing private and institutional ATXA investors, many of whom have pharmaceutical and/or entrepreneurial expertise. These funds have been deployed exactly as planned, to fund the Phase II-enabling studies, meaning ATXA is now primed to begin the Phase II clinical trials.

Key highlights:

• More than €17M has been invested in ATXA since 2019, with Enterprise Ireland, EU Horizon - and EIC Accelerator - programs alone providing €10 million through grant and equity funding. Other investors into the company include a mix of serial expert pharma investors based in the USA, UK and Ireland, as well as family offices, high net worth individuals with prior business expertise along with the founder and members of the senior management team at ATXA.
• To date, company has secured 16 granted patents globally, and the exciting pre-clinical data has moved the FDA and EMA to give NTP42 extended protection from competition by awarding it “Orphan Drug Status”.
• NTP42 has already been tested in a Phase I clinical trial in 79 healthy volunteers, where it was confirmed as safe, well tolerated and only needs to be taken once daily at low doses for clinical effect.
• Furthermore, since the last fundraising exercise, ATXA has carried out a second and very successful Bridging Clinical trial testing the Capsule form of NTP42 in an additional 13 healthy men and women. Thus, between the two completed clinical trials, NTP42 has been clinically tested, and confirmed as a safe, well tolerated and excellent therapeutics drug candidate in a combined total of 92 men and women.
• Based on this novel Capsule technology, a new patent was also filed which, when granted, will extend protection of NTP42 globally until 2045, a valuable commercial asset. Assuming annual global sales earnings of €1Billion for NTP42, extending patent protection from the current 2036 to 2045 gives additional premium earnings in excess of €9Billion to the ATXA large pharma M&A acquirer or NTP42 licensor representing, as stated, a truly valuable commercial asset enormously increasing valuation of both the company and drug asset.  Note that despite the enormous achievement made by ATXA since the last Spark Crowdfunding raise (closed in May 2024), the company has not increased the cost of its shares to the Spark investors in this new investment raise.  Thus, Spark investors can buy into ATXA’s opportunity at a 50% discount to professional investors thanks to EIIS-eligibility, and at the same share price as the last raise. This truly is an exclusive opportunity to invest at low cost in a clinical-stage pharma-business that has global reach and ambition.